Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,015 JPY | -0.50% | +1.39% | +12.94% |
Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 23.1 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.94% | 723M | - | ||
+30.38% | 684B | C+ | ||
+26.51% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 329B | B- | ||
+3.73% | 284B | C+ | ||
+16.70% | 240B | B+ | ||
+8.78% | 208B | B- | ||
-7.93% | 200B | A+ | ||
+7.68% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4551 Stock
- Ratings Torii Pharmaceutical Co., Ltd.